Main > > >DRUG DEVELOPMENT (ONCOLOGY). *

---

Onco.>Drug Development>IntraTumoral MicroDosing Platform.
Arrayed Microinjection.
Comparative In Vivo Oncology.
Description>Phase 0 Trials:
By coupling the platform with the FDA s guidance on exploratory IND, Company has identified a path to rapidly evaluate multiple drug candidates, but without the costs and time associated with a traditional phase 1 clinical trial.
Phase 0 trials—use minute amounts of drugs to assess their pharmacodynamics effects in patients.
Unlike traditional phase 1 clinical trials that expose patients to far higher doses of investigational drugs, and therefore an increased risk of toxicity, intratumoral microdosing uses approximately 100-fold lower doses of drug candidates.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.09.


>DRUG DEVELOPMENT (ONCOLOGY). *'s products
This section has no products